Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ASP3082 in KRAS G12D-Mutated Solid Tumors
jRCT2031220738Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of setidegrasib in Non-hematologic malignancy, pancreatic adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities (DLTs), Adverse Events (AEs) and 6 more. Started Jun 2023; status: recruiting.
02
Drugs
setidegrasib
03
Conditions
Non-hematologic malignancypancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220738.